-
-
-
-
-
-
-
Dynavax Reports Third Quarter 2021 Financial Results
-
-
-
-
-
-
-
Dynavax Reports First Quarter 2018 Financial Results
-
-
-
-
-
-
-
Dynavax Secures $175 Million in Non-Dilutive Debt Financing
-
-
-
-
-
-
-
After-Hours Stock Movers 08/03: (YELP) (WTW) (ANET) Higher; (AAOI) (PI) (SYNA) Lower (more...)
-
-
-
-
-
-
-
Dynavax (DVAX) Halted Ahead of FDA Advisory Committee Meeting
-
-
-
-
-
-
-
Dynavax Announces FDA Acceptance for Review of Its Complete Response to November 2016 CRL and PDUFA Action Date for HEPLISAV-B(TM)
-
-
-
-
-
-
-
Dynavax Presents Data Showing That HEPLISAV-B Provides Significantly Higher Seroprotection Rates Against Hepatitis B Infection in Populations Known to Have a Reduced Immune Response to Currently Licen
-
12,639 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All